3P Biopharmaceuticals receives FDA approval

Wednesday September 18th, 2019 | General

The FDA classified 3P facilities as acceptable for the manufacture of the target molecule, and appropriate for its commercialization in the US market, once the product is authorized. 3P Biopharmaceuticals a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection […]

3P Biopharmaceuticals enters into manufacturing agreement with the Swedish company Affibody

Thursday June 6th, 2019 | General

The arrangement covers process transfer, process development and GMP manufacture of Affibody’s candidate 3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics, has signed a collaboration agreement with the Swedish company Affibody for the process transfer, scale-up and GMP commercial manufacturing of a recombinant protein sole property of Affibody. […]